Prestige Consumer Healthcare (PBH) reported a challenging fourth quarter, with revenues of $281.6 million, down 5% year-over-year, primarily due to lower sales in the Eye and Ear Care segment and disruptions in Middle East shipping. For the fiscal year, the company experienced a 4.5% organic revenue decline, with North America seeing a 4.9% drop. Adjusted diluted EPS fell to $4.38, reflecting the impact of decreased sales despite a lower share count and reduced interest expenses.
The company’s long-term outlook remains cautiously optimistic, with fiscal 2027 guidance projecting revenues between $1.1 billion and $1.12 billion, indicating a return to organic growth. Management is focused on ramping up Eye Care production following the acquisition of Pillar5, which is expected to enhance output significantly in the latter half of the year. Additionally, pending acquisitions of Breathe Right and LaCorium Health are anticipated to diversify the portfolio and drive future growth.
Market professionals should note that while current performance is hindered by supply chain issues and a tough consumer environment, the strategic investments in production capabilities and acquisitions position Prestige for potential recovery and growth in the coming fiscal year.
Source: fool.com